Thursday, June 26, 2025 6/26/2025

Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer

Award Number: R01CA257610
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/09/2021
PERIOD OF PERFORMANCE END DATE: 01/31/2026

Group Awards By:

View Award Description

Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer - Abstract Prostate cancer (PC) afflicts more men in the U.S. than any other malignancy and is the second leading cause of cancer death in this population. Recently, new therapies have improved survival in some men but have offered little benefit to others. Tissue profiling has identified genes and pathways associated with resistance and progression to advanced disease, but little is known about the dynamics of when and how such changes arise during therapy. Such insights can only be gained through minimally invasive monitoring that allows repeated disease profiling over time. Our multidisciplinary team has developed and tested two such minimally invasive monitoring capabilities: The first is multi-parametric liquid biopsy: streamlined analysis of blood samples that simultaneously measures PC-relevant cellular and molecular features from single circulating tumor cells and matched plasma cell-free nucleic acids. The second is radiomic analysis: high-throughput extraction of quantitative metrics to identify PC-relevant phenomic imaging features. By synergizing the strengths of the two methods, our goal is to test the hypothesis that liquid biopsy and radiomic techniques can be applied jointly to monitor metastatic PC noninvasively over time, culminating in new prognostic and predictive tools to guide therapy. To maximize the impact of our findings, liquid biopsy profiling and radiomic analysis will be integrated into Southwest Oncology (SWOG) S1802, a phase 3 prospective therapeutic trial for over 1200 men with newly diagnosed metastatic castrate sensitive prostate cancer (mCSPC) treated with standard systemic therapy alone or in combination with definitive treatment of the primary tumor. Notably, SWOG and the other participating cooperative groups have reviewed and approved this proposal (see Letters of Support), and the requisite blood samples and CT scans already are being collected as part of the active protocol. In this unique setting, we will pursue three Specific Aims. We will: 1. Use multi-parametric liquid biopsies to monitor the evolving cellular and molecular landscape of mCSPC during treatment in S1802; 2. Use radiomic analysis of CT scans to monitor the evolving radiographic landscape of mCSPC during treatment in S1802; and 3. Integrate cellular, molecular, and radiomic data to develop composite disease monitoring models predictive of PFS and OS. Importantly, liquid biopsies and CT images will be matched within patients and analyzed at key inflection points over the course of the trial: at diagnosis, after initiation of systemic therapy, after definitive therapy, and at disease progression. In this way, the proposed work will illuminate when and how PC-relevant phenotypes arise during therapy, and how they relate to clinical outcomes. In particular, we will better understand which components of the liquid biopsy – circulating cells, plasma, or both – most accurately reflect the tumor's evolving molecular profile, which radiomic metrics most closely correlate with these molecular features and can serve as early cost-effective indicators of emerging resistance, and which composite models combining liquid biopsy and radiomic features best predict PFS and OS and can serve as powerful minimally-invasive tools to monitor and adjust therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $689,813 )
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	002	5	6/2/2025	NON-COMPETING CONTINUATION	$68,980
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	5	1/7/2025	NON-COMPETING CONTINUATION	$620,833
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	001	5	2/14/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $689,813

Issue Date FY: 2024 ( Subtotal = $655,325 )
2024	2024	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90089	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	001	4	4/18/2024	NON-COMPETING CONTINUATION	$34,491
2024	2024	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90089	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	4	1/25/2024	NON-COMPETING CONTINUATION	$620,834
														Subtotal = $655,325

Issue Date FY: 2023 ( Subtotal = $676,022 )
2023	2023	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST	LOS ANGELES	CA	90089	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	3	1/27/2023	NON-COMPETING CONTINUATION	$676,022
														Subtotal = $676,022

Issue Date FY: 2022 ( Subtotal = $676,023 )
2022	2022	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90007	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	001	2	5/24/2022	NON-COMPETING CONTINUATION	$55,185
2022	2022	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90007	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	2	1/11/2022	NON-COMPETING CONTINUATION	$620,838
														Subtotal = $676,023

Issue Date FY: 2021 ( Subtotal = $706,071 )
2021	2021	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90007	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	1	2/9/2021	NEW	$706,071
														Subtotal = $706,071

Grand Total All Awards = $3,403,254

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer

Award Number: R01CA257610

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/09/2021

PERIOD OF PERFORMANCE END DATE: 01/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer